AU740318B2 - Dihydropyrimidines - Google Patents

Dihydropyrimidines Download PDF

Info

Publication number
AU740318B2
AU740318B2 AU38133/99A AU3813399A AU740318B2 AU 740318 B2 AU740318 B2 AU 740318B2 AU 38133/99 A AU38133/99 A AU 38133/99A AU 3813399 A AU3813399 A AU 3813399A AU 740318 B2 AU740318 B2 AU 740318B2
Authority
AU
Australia
Prior art keywords
alkyl
compounds
phenyl
formula
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU38133/99A
Other languages
English (en)
Other versions
AU3813399A (en
Inventor
Karl Deres
Siegfried Goldmann
Erwin Graef
Thomas Kramer
Stefan Lottmann
Ulrich Niewohner
Arnold Paessens
Karl-Heinz Schlemmer
Jurgen Stoltefuss
Jorn Stolting
Olaf Weber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Intellectual Property GmbH
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Publication of AU3813399A publication Critical patent/AU3813399A/en
Application granted granted Critical
Publication of AU740318B2 publication Critical patent/AU740318B2/en
Assigned to BAYER SCHERING PHARMA AKTIENGESELLSCHAFT reassignment BAYER SCHERING PHARMA AKTIENGESELLSCHAFT Alteration of Name(s) in Register under S187 Assignors: BAYER AKTIENGESELLSCHAFT
Assigned to BAYER INTELLECTUAL PROPERTY GMBH reassignment BAYER INTELLECTUAL PROPERTY GMBH Alteration of Name(s) in Register under S187 Assignors: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Saccharide Compounds (AREA)
AU38133/99A 1998-04-18 1999-04-07 Dihydropyrimidines Expired AU740318B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19817264A DE19817264A1 (de) 1998-04-18 1998-04-18 Neue Dihydropyrimidine
DE19817264 1998-04-18
PCT/EP1999/002344 WO1999054326A1 (de) 1998-04-18 1999-04-07 Dihydropyrimidine

Publications (2)

Publication Number Publication Date
AU3813399A AU3813399A (en) 1999-11-08
AU740318B2 true AU740318B2 (en) 2001-11-01

Family

ID=7864972

Family Applications (1)

Application Number Title Priority Date Filing Date
AU38133/99A Expired AU740318B2 (en) 1998-04-18 1999-04-07 Dihydropyrimidines

Country Status (36)

Country Link
US (3) US6696451B1 (enExample)
EP (1) EP1080086B1 (enExample)
JP (2) JP4590097B2 (enExample)
KR (1) KR100636771B1 (enExample)
CN (1) CN1159311C (enExample)
AR (1) AR018187A1 (enExample)
AT (1) ATE223401T1 (enExample)
AU (1) AU740318B2 (enExample)
BG (1) BG64649B1 (enExample)
BR (2) BR9909730B1 (enExample)
CA (1) CA2328780C (enExample)
CO (1) CO5021127A1 (enExample)
CU (1) CU23049A3 (enExample)
CZ (1) CZ293482B6 (enExample)
DE (2) DE19817264A1 (enExample)
DK (1) DK1080086T3 (enExample)
ES (1) ES2183548T3 (enExample)
GT (1) GT199900056A (enExample)
HU (1) HUP0102372A3 (enExample)
ID (1) ID27263A (enExample)
IL (2) IL138584A0 (enExample)
MY (1) MY126527A (enExample)
NO (2) NO321985B1 (enExample)
NZ (1) NZ507569A (enExample)
PE (1) PE20000427A1 (enExample)
PL (1) PL193898B1 (enExample)
PT (1) PT1080086E (enExample)
RU (1) RU2245881C9 (enExample)
SI (1) SI1080086T1 (enExample)
SK (1) SK286407B6 (enExample)
SV (1) SV1999000047A (enExample)
TR (1) TR200003011T2 (enExample)
TW (1) TW548274B (enExample)
UA (1) UA63998C2 (enExample)
WO (1) WO1999054326A1 (enExample)
ZA (1) ZA200005136B (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000058302A1 (de) * 1999-03-25 2000-10-05 Bayer Aktiengesellschaft Dihydropyrimidine und ihre verwendung zur behandlung von hepatitis b
WO2000078730A1 (en) 1999-06-23 2000-12-28 Ajinomoto Co., Inc. Novel dihydropyrimidine derivatives
WO2001045712A1 (de) * 1999-12-22 2001-06-28 Bayer Aktiengesellschaft Arzneimittelkombinationen gegen virale erkrankungen
DE10012823A1 (de) 2000-03-16 2001-09-20 Bayer Ag Arzneimittel gegen virale Erkrankungen
DE10013125A1 (de) * 2000-03-17 2001-09-20 Bayer Ag Arzneimittel gegen virale Erkrankungen
DE10013126A1 (de) * 2000-03-17 2001-09-20 Bayer Ag Arzneimittel gegen virale Erkrankungen
DE10125131A1 (de) 2001-05-23 2002-12-05 Bayer Ag Verfahren zur Spaltung des Methyl 4-(2-chlor-4-fluorphenyl)-2-(3,5-difluor-2-pyridinyl)-6-methyl-1,4-dihydro-5-pyrmidincarboxylat-Racemats
US20040092735A1 (en) * 2002-11-08 2004-05-13 Orchid Chemicals & Pharmaceuticals Limited Process for the preparation of cefuroxime sodium
CN101104617B (zh) * 2006-07-10 2010-06-23 北京摩力克科技有限公司 二氢嘧啶类化合物及其用于制备治疗和预防病毒性疾病的药物的用途
CN101104604B (zh) 2006-07-10 2011-03-02 北京摩力克科技有限公司 光学纯二氢嘧啶类化合物及其用于制备治疗和预防病毒性疾病的药物的用途
RU2452733C2 (ru) * 2007-04-27 2012-06-10 Пэдью Фарма Л.П. Антагонисты trpv1 и их применение
PT2514750E (pt) * 2007-06-18 2014-01-23 Sunshine Lake Pharma Co Ltd Tiazolil dihidropirimidinas substituídas com bromo-fenilo
NZ582443A (en) 2007-07-12 2011-04-29 Novartis Ag Oral pharmaceutical solutions containing telbivudine
US20130267517A1 (en) 2012-03-31 2013-10-10 Hoffmann-La Roche Inc. Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
MY182403A (en) * 2012-08-24 2021-01-25 Sunshine Lake Pharma Co Ltd Dihydropyrimidine compounds and their application in pharmaceuticals
CA2881322A1 (en) 2012-09-10 2014-03-13 F. Hoffmann-La Roche Ag 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
CN103664899B (zh) * 2012-09-11 2017-06-16 广东东阳光药业有限公司 杂芳基取代的二氢嘧啶类化合物及其在药物中的应用
HK1215030A1 (zh) * 2012-11-09 2016-08-12 Indiana University Research And Technology Corporation 用於hbv組裝效應劑的替代用途
BR102014028162A2 (pt) * 2013-11-12 2015-09-08 Dow Agrosciences Llc processo para fluoração de compostos
CA2920415A1 (en) 2013-11-19 2015-05-28 Sunshine Lake Pharma Co., Ltd. Dihydropyrimidine compounds and their application in pharmaceuticals
KR102284944B1 (ko) 2013-11-27 2021-08-03 선샤인 레이크 파르마 컴퍼니 리미티드 다이하이드로피리미딘 유도체 및 이의 중간산물의 제조 방법
MX2016012573A (es) 2014-03-28 2018-02-19 Sunshine Lake Pharma Co Ltd Compuestos de dihidropirimidina y su aplicacion en productos farmaceuticos.
CN105153164B (zh) * 2014-05-30 2018-10-30 齐鲁制药有限公司 作为hbv抑制剂的二氢嘧啶并环衍生物
EP3150600B1 (en) * 2014-05-30 2018-06-27 Qilu Pharmaceutical Co., Ltd. Dihydropyrimido loop derivative as hbv inhibitor
AU2016214799A1 (en) 2015-02-07 2017-06-15 Sunshine Lake Pharma Co., Ltd. Complexes and salts of dihydropyrimidine derivatives and their application in pharmaceuticals
EP3645516A4 (en) 2017-06-27 2021-07-07 Janssen Pharmaceutica NV HETEROARYLDIHYDROPYRIMIDE DERIVATIVES AND METHODS OF TREATMENT OF HEPATITIS B INFECTIONS
US10759774B2 (en) 2017-09-28 2020-09-01 The Curators Of The University Of Missouri Inhibitors of hepatitis B virus targeting capsid assembly
EA202091113A1 (ru) 2017-11-02 2020-08-28 Айкурис Гмбх Унд Ко. Кг Новые высокоактивные аминотиазолзамещенные индол-2-карбоксамиды, активные в отношении вируса гепатита b (hbv)
MX2020004838A (es) 2017-11-02 2020-10-16 Aicuris Gmbh & Co Kg Nuevas indol-2-carboxamidas sustituidas con pirazolopiperidina, de alta actividad, activas contra el virus de la hepatitis b (vhb).
EP3790866A4 (en) * 2018-05-08 2022-03-02 Janssen Sciences Ireland Unlimited Company DIHYDROPYRIMIDINE DERIVATIVES AND THEIR USES IN THE TREATMENT OF HEPATITIS B VIRUS INFECTION OR HEPATITIS B VIRUS INDUCED DISEASES
US11053235B2 (en) 2018-08-09 2021-07-06 Janssen Sciences Ireland Unlimited Company Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases
PY1991606A (es) 2018-11-02 2022-02-10 Aicuris Gmbh & Co Kg Nueva urea 6,7-dihidro-4h-pirazolo [4,3-c] piridinas activas contra el virus de la hepatitis b (vhb)
US20220009945A1 (en) * 2018-11-02 2022-01-13 Aicuris Gmbh & Co. Kg Novel urea 6,7-dihydro-4h-thiazole[5,4-c]pyridines active against the hepatitis b virus (hbv)
PY1991611A (es) 2018-11-02 2022-03-14 Aicuris Gmbh & Co Kg Nueva urea 6,7-dihidro-4h-pirazolo [1,5-a] pirazinas activas contra el virus de la hepatitis b (vhb)
UY38434A (es) 2018-11-02 2020-05-29 Aicuris Gmbh & Co Kg Nuevas 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activas contra el virus de la hepatitis b (hbv)
AR116947A1 (es) 2018-11-02 2021-06-30 Aicuris Gmbh & Co Kg Derivados de urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas-indol-2-carboxamidas activas contra el virus de la hepatitis b (vhb)
AR117188A1 (es) 2018-11-02 2021-07-21 Aicuris Gmbh & Co Kg Derivados de urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas activas contra el virus de la hepatitis b (vhb)
CA3124317A1 (en) 2018-12-20 2020-06-25 Janssen Pharmaceutica Nv Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis b infections
EP3962909B1 (en) 2019-04-30 2023-10-04 AiCuris GmbH & Co. KG Novel oxalyl piperazines active against the hepatitis b virus (hbv)
MX2021013086A (es) 2019-04-30 2021-11-17 Aicuris Gmbh & Co Kg Nuevas fenil y piridil ureas activas contra el virus de la hepatitis b (vhb).
US20220306647A1 (en) 2019-04-30 2022-09-29 Aicuris Gmbh & Co. Kg Novel indole-2-carboxamides active against the hepatitus b virus (hbv)
KR20220002498A (ko) 2019-04-30 2022-01-06 아이쿠리스 게엠베하 운트 코. 카게 B형 간염 바이러스 (hbv)에 대해 활성인 신규 인돌리진-2-카르복스아미드
WO2020255016A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL130304C (enExample) * 1964-02-12
CH550189A (de) 1971-01-08 1974-06-14 Ciba Geigy Ag Verfahren zur herstellung von neuen dibenzo (b,f) thiepincarbonsaeuren.
CH569043A5 (enExample) 1973-01-23 1975-11-14 Ciba Geigy Ag
US4371537A (en) * 1981-08-13 1983-02-01 The Dow Chemical Company Sulfur-substituted phenoxypyridines having antiviral activity
DE3234684A1 (de) 1982-09-18 1984-03-22 Bayer Ag, 5090 Leverkusen Neue dihydropyrimidine, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
JPS60185764A (ja) * 1984-03-05 1985-09-21 Wako Pure Chem Ind Ltd ピリジン誘導体の新規な製造法
US4698340A (en) * 1984-07-19 1987-10-06 Fujisawa Pharmaceutical Co., Ltd. Pyrimidine derivatives, processes for preparation thereof and composition containing the same
US4727073A (en) 1984-10-01 1988-02-23 Fujisawa Pharmaceutical Co., Ltd. Pyrimidine derivatives and composition of the same
GB8906168D0 (en) * 1989-03-17 1989-05-04 Pfizer Ltd Therapeutic agents
EP0941222A2 (en) 1996-11-12 1999-09-15 Novartis AG Pyrazole derivatives useful as herbicides
SE9702564D0 (sv) 1997-07-02 1997-07-02 Astra Ab New compounds

Also Published As

Publication number Publication date
BR9909730A (pt) 2000-12-19
SI1080086T1 (en) 2003-02-28
TR200003011T2 (tr) 2001-01-22
EP1080086B1 (de) 2002-09-04
IL138584A0 (en) 2001-10-31
CA2328780C (en) 2008-09-23
PL193898B1 (pl) 2007-03-30
ES2183548T3 (es) 2003-03-16
BRPI9917862A2 (enExample) 2010-12-07
CN1159311C (zh) 2004-07-28
JP5237332B2 (ja) 2013-07-17
CN1305471A (zh) 2001-07-25
UA63998C2 (uk) 2004-02-16
WO1999054326A8 (de) 1999-12-29
PT1080086E (pt) 2002-12-31
BG64649B1 (bg) 2005-10-31
AU3813399A (en) 1999-11-08
RU2245881C9 (ru) 2006-02-10
TW548274B (en) 2003-08-21
PL343481A1 (en) 2001-08-27
NO321985B1 (no) 2006-07-31
SK286407B6 (sk) 2008-09-05
US6696451B1 (en) 2004-02-24
NO20005215L (no) 2000-12-13
PE20000427A1 (es) 2000-06-25
NZ507569A (en) 2002-04-26
DE19817264A1 (de) 1999-10-21
HUP0102372A3 (en) 2003-01-28
KR20010042788A (ko) 2001-05-25
DE59902573D1 (en) 2002-10-10
ID27263A (id) 2001-03-22
CO5021127A1 (es) 2001-03-27
US7514565B2 (en) 2009-04-07
BRPI9917862B1 (pt) 2013-05-07
US20070117812A1 (en) 2007-05-24
DK1080086T3 (da) 2002-12-23
BG104812A (en) 2001-06-29
RU2245881C2 (ru) 2005-02-10
CZ20003871A3 (cs) 2001-01-17
NO20005215D0 (no) 2000-10-17
HUP0102372A2 (hu) 2001-12-28
IL138584A (en) 2006-09-05
BRPI9917862B8 (pt) 2021-05-25
EP1080086A1 (de) 2001-03-07
JP2010241837A (ja) 2010-10-28
JP4590097B2 (ja) 2010-12-01
SV1999000047A (es) 2000-06-23
HK1039119A1 (en) 2002-04-12
BR9909730B1 (pt) 2012-09-04
US20040167135A1 (en) 2004-08-26
ZA200005136B (en) 2001-03-02
CU23049A3 (es) 2005-06-24
JP2002512243A (ja) 2002-04-23
NO20045259L (no) 2000-12-13
AR018187A1 (es) 2001-10-31
KR100636771B1 (ko) 2006-10-23
WO1999054326A1 (de) 1999-10-28
CZ293482B6 (cs) 2004-05-12
CA2328780A1 (en) 1999-10-28
SK15652000A3 (sk) 2001-04-09
GT199900056A (es) 2000-10-07
ATE223401T1 (de) 2002-09-15
MY126527A (en) 2006-10-31
NO329020B1 (no) 2010-07-26

Similar Documents

Publication Publication Date Title
US6696451B1 (en) Dihydropyrimidines
US20040132730A1 (en) Inhibitors of TGFbeta
EP1107973B1 (en) NOVEL THIENO[2,3-d]PYRIMIDINEDIONES, PROCESS FOR THEIR PREPARATION AND USE THEREOF IN THERAPY
BG65106B1 (bg) Заместени 2-арил-3-(хетероарил)-имидазо[1,2-а]пиримидини, лекарствени средства, които ги съдържат, използването им и метод за тяхното получаване
US8188091B2 (en) Tetrahydroquinazoline compounds and their use in preparing medicaments for treating and preventing virosis
DE10237883A1 (de) Substituierte Isoxazolderivate und ihre Verwendung in der Pharmazie
JP2009508838A (ja) 新規のピリミジン・カルボキサミド
WO2002022588A1 (en) Novel pyrimidine derivative and novel pyridine derivative
US6403596B1 (en) Substituted pyridones having cytokine inhibitory activity
EP0257616B1 (en) Dihydropyridine derivates and pharmaceutical composition thereof
US20060247233A1 (en) Thiazoles inhibitors of the alk-5 receptor
CA1323876C (en) Dihydropyridine derivatives and pharmaceutical composition thereof
HUT65885A (en) Process for preparing heterocyclyl-phenoxyalkyl-piperidinylpyridazines and pharmaceutical compositions containing them
SK155395A3 (en) Naphtyridine derivatives, preparation method thereof and pharmaceutical compositions containing them
JPH0240383A (ja) 1,4−ジヒドロピリジン誘導体
TWI835344B (zh) 新穎蛋白殼組裝抑制劑
SK47794A3 (en) Chinolyl-dihydropyridinecarboxylic acid esters, method of their production, medicines containing these matters, method of their production and using of these compounds
EP0189254A1 (en) Dihydropyridine anti-ischaemic and antihypertensive agents
MXPA00010153A (en) Dihydropyrimidines

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired